Journal of Diagnostics Concepts & Practice >

2019 , Vol. 18 >Issue 04: 402 - 411

DOI: https://doi.org/10.16150/j.1671-2870.2019.04.005

Original articles

Screening and identification of clinical molecular targets in papillary thyroid cancers

Expand
  • 1. Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine,Shanghai 200025, China
    2. Department of Clinical Laboratory, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 201801, China
    3. Department of Clinical Laboratory, Children’s Hospital of Shanghai Jiao Tong University, Shanghai 200040, China
    4. Capital Medical University of Basic Medicine, Beijing 100054, China
    5. Central Laboratory, Shanghai Jiading District Central Hospital, Shanghai University of Medicine & Health Sciences, Shanghai 201800, China

Received date: 2018-10-22

  Online published: 2019-08-25

Fold

Abstract

Objective: To identify the clinical molecular targets in papillary thyroid cancer (PTC) by analyzing the diffe-rential expression of the NF-κB signal pathway related genes and mutations of 52 solid tumor-related genes in PTC against normal adjacent tissue (NAT). Methods: RNA and DNA of tumor and NAT were extracted from formalin-fixed paraffin-embedded (FFPE) tissue of 20 papillary thyroid cases. The mRNA and protein expressions of NF-κB signal pathway related gene CD44, BCL2, CCND2, c-FLIP, IκBα, A20 and ABINs were detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemistry, respectively. Mutations in 5 relapse cases were detected by targeted next-generation sequencing (NGS). Results: Expressions of CD44 and CCND2 were significantly higher at both RNA and protein level in PTC tumor tissue than those in NAT. The expressions of NF-κB signal pathway related genes were not significantly different between PTC having and not having lymph node metastasis. Results of NGS showed that ALK, BRAF, FGFR3/4, KIT, MYC and MAPK signal pathway genes HRAS, KRAS, NRAS, RET were mutated in PTC cases with a high frequency. Two cases had 35 and 40 mutation genes, respectively, and having high tumor burden; clinical data showed that these two were relapse cases after operation. BRAF V600E mutation was not always a tumor specific mutation (64%), but also could be a germline mutation (29%). Real-time quantitative PCR (qPCR) and NGS had a high consistent rate (80%) for the detection of V600E mutation. Conclusions: The high expressions of CD44 and CCND2 in PTC tumor tissue and the tumor specific mutations in BRAF, RAS, FGFRs, KIT and MYC genes might be used as clinical molecular markers for selection of targeted therapy of individual PTC patient. NGS and qPCR had high consistence for detection of BRAF V600E, and used jointly could improve the detection rate.

Key words： Papillary thyroid cancer; Real-time quantitative PCR (qPCR); Targeted sequencing; NF-κB target genes; BRAF V600E mutation

Cite this article

YANG Chihui, ZHANG Jing, MENG Leijun, GONG Liping, CHANG Qing, ZHANG Hong, ZENG Naiyan . Screening and identification of clinical molecular targets in papillary thyroid cancers[J]. Journal of Diagnostics Concepts & Practice, 2019 , 18(04) : 402 -411 . DOI: 10.16150/j.1671-2870.2019.04.005

References

[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[2] Sherman SI. Thyroid carcinoma[J]. Lancet, 2003, 361(9356):501-511.
[3] Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013[J]. JAMA, 2017, 317(13):1338-1348.
[4] Sipos JA, Mazzaferri EL. The therapeutic management of differentiated thyroid cancer[J]. Expert Opin Pharmacother, 2008, 9(15):2627-2637.
[5] Albores-Saavedra J, Henson DE, Glazer E, et al. Chan-ging patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study[J]. Endocr Pathol, 2007, 18(1):1-7.
[6] O'Neill CJ, Oucharek J, Learoyd D, et al. Standard and emerging therapies for metastatic differentiated thyroid cancer[J]. Oncologist, 2010, 15(2):146-156.
[7] Chen H, Luthra R, Routbort MJ, et al. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy[J]. Mol Cancer Ther, 2018, 17(7):1575-1584.
[8] Hunt J. Understanding the genotype of follicular thyroid tumors[J]. Endocr Pathol, 2005, 16(4):311-321.
[9] Nikiforova MN, Wald AI, Roy S, et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer[J]. J Clin Endocrinol Metab, 2013, 98(11):E1852-E1860.
[10] Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study[J]. J Clin Endocrinol Metab, 2008, 93(10):3943-3949.
[11] Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications[J]. Endocr Rev, 2007, 28(7):742-762.
[12] Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer[J]. Ann Surg, 2007, 246(3):466-470.
[13] O'Neill CJ, Bullock M, Chou A, et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer[J]. Surgery, 2010, 148(6):1139-1145.
[14] Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentia-ted papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane[J]. Endocr Relat Cancer, 2006, 13(1):257-269.
[15] Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism[J]. J Clin Endocrinol Metab, 2007, 92(7):2840-2843.
[16] Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer[J]. Nature, 2004, 431(7007):461-466.
[17] Xue X, Zeng N, Gao Z, et al. Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR[J]. Lab Invest, 2015, 95(1):113-120.
[18] Pan LX, Diss TC, Peng HZ, et al. Clonality analysis of defined B-cell populations in archival tissue sections usi-ng microdissection and the polymerase chain reaction[J]. Histopathology, 1994, 24(4):323-327.
[19] Nanda SK, Venigalla RK, Ordureau A, et al. Polyubiquitin binding to ABIN1 is required to prevent autoimmunity[J]. J Exp Med, 2011, 208(6):1215-1228.
[20] Takano T, Sumizaki H, Nakano K, et al. Increased expression of CD44 variants in differentiated thyroid cancers[J]. Jpn J Cancer Res, 1996, 87(12):1245-1250.
[21] Orian-Rousseau V, Chen L, Sleeman JP, et al. CD44 is required for two consecutive steps in HGF/c-Met signa-ling[J]. Genes Dev, 2002, 16(23):3074-3086.
[22] Samant RS, Clark DW, Fillmore RA, et al. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation[J]. Mol Cancer, 2007, 6:6.
[23] Bourguignon LY, Shiina M, Li JJ. Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression[J]. Adv Cancer Res, 2014, 123:255-275.
[24] Misra S, Hascall VC, Berger FG, et al. Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer[J]. Connect Tissue Res, 2008, 49(3):219-224.
[25] Sacks JD, Barbolina MV. Expression and Function of CD44 in Epithelial Ovarian Carcinoma[J]. Biomolecules, 2015, 5(4):3051-3066.
[26] Fan Z, Cui H, Xu X, et al. MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3[J]. Oncotarget, 2015, 6(28):25266-25280.
[27] Schmidt BA, Rose A, Steinhoff C, et al. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors[J]. Cancer Res, 2001, 61(10):4214-4221.
[28] Bartkova J, Thullberg M, Slezak P, et al. Aberrant expression of G1-phase cell cycle regulators in flat and exo-phytic adenomas of the human colon[J]. Gastroenterology, 2001, 120(7):1680-1688.
[29] Shan YS, Hsu HP, Lai MD, et al. Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer[J]. Oncol Lett, 2017, 14(4):4517-4526.
[30] Khanna V, Eide CA, Tognon CE, et al. Recurrent cyclin D2 mutations in myeloid neoplasms[J]. Leukemia, 2017, 31(9):2005-2008.
[31] Wang L, Cui Y, Zhang L, et al. The Silencing of CCND2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between CCND2 Methylation Status and Clinical Features[J]. PLoS One, 2016, 11(9):e0161859.
[32] Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma[J]. Cancer Res, 2003, 63(7):1454-1457.
[33] Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma[J]. J Natl Cancer Inst, 2003, 95(8):625-627.
[34] Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer[J]. J Clin Invest, 2005, 115(1):94-101.
[35] Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer[J]. N Engl J Med, 2013, 368(7):623-632.
[36] Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2005, 90(12):6373-6379.
[37] Sabra MM, Dominguez JM, Grewal RK, et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases[J]. J Clin Endocrinol Metab, 2013, 98(5):E829-E836.
[38] COSMIC. Complete Data for Gene-ALK[DB/OL]. [2019-05-17]. https://cancer.sanger.ac.uk/cosmic/gene/samples?all_data=&coords=AA%3AAA&dr=&end=1621&gd=&id=50&ln=ALK&mut_pie1=CzG&seqlen=1621&src=gene&start=1.
[39] Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-mediated carcinogenesis[J]. Biochim Biophys Acta, 2012, 1823(4):850-860.
[40] Dienstmann R, Rodon J, Prat A, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors[J]. Ann Oncol, 2014, 25(3):552-563.
[41] Kelleher FC, O'Sullivan H, Smyth E, et al. Fibroblast growth factor receptors, developmental corruption and malignant disease[J]. Carcinogenesis, 2013, 34(10):2198-2205.
[42] COSMIC. Complete Data for Gene-FGFR3[DB/OL]. [2019-05-17]. https://cancer.sanger.ac.uk/cosmic/gene/samples?all_data=&coords=AA%3AAA&dr=&end=807&gd=&id=9&ln=FGFR3&mut_pie1=AzG&seqlen=807&src=gene&start=1.
[43] My Cancer Genome. KIT[DB/OL]. [2019-05-17]. https://www.mycancergenome.org/content/gene/kit/.
[44] Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor[J]. J Clin Oncol, 2003, 21(23):4342-4349.
[45] Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J]. Science, 1998, 279(5350):577-580.
[46] NCBI ClinVar. NM_000222.2(KIT):c.1648_1674del27 (p.Lys550_Lys558del) Variation Report[DB/OL]. [2019-05-17]. https://www.ncbi.nlm.nih.gov/clinvar/variation/13857/.
[47] Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors[J]. Cancer Treat Rev, 2016, 42:47-55.
[48] My Cancer Genome. MYC[DB/OL]. [2019-05-17]. https://www.mycancergenome.org/content/gene/myc/.
[49] NCBI ClinVar. NM_002467.5(MYC):c.218C>T (p.Thr73Ile) Variation Report[DB/OL]. [2019-05-17]. https://www.ncbi.nlm.nih.gov/clinvar/variation/376300/.
[50] Han B, Cui H, Kang L, et al. Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway[J]. Tumour Biol, 2015, 36(8):6295-6304.
Options
Outlines

/

〈 〉